Pinnacle Associates’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$412K Sell
10,756
-470
-4% -$12.3K ﹤0.01% 743
2026
Q1
$238K Buy
+11,226
New +$224K ﹤0.01% 870

Other funds holding TXG

Pinnacle Associates's TXG Position: Q2 2026 in Review

Pinnacle Associates reduced its 10x Genomics (TXG) stake by 4.2% in Q2 2026, selling an estimated $12.3K and leaving 10,756 shares worth $412K. The position accounts for ﹤0.01% of the portfolio, ranked #743.

Pinnacle Associates first reported a position in TXG in Q1 2026 and has held it in 2 quarters since. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Pinnacle Associates held 10,756 shares of 10x Genomics worth $412K as of Q2 2026.
  • Pinnacle Associates sold 470 10x Genomics shares in Q2 2026, an estimated $12.3K.
  • 10x Genomics made up ﹤0.01% of Pinnacle Associates's portfolio in Q2 2026, its #743 holding.
  • Pinnacle Associates first reported a position in 10x Genomics in Q1 2026 and has held it in 2 quarters since.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Pinnacle Associates's 13F filing for Q2 2026, filed 3 Aug 2026.